Advanced Malignancies Clinical Trial
Official title:
A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA 32459 for expansion (RDE) and the maximum tolerated dose (MTD). Part 2 (dose expansion) will further evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of INCA 32459 at the recommended dose(s) for expansion in 2 tumor-specific cohorts.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | April 10, 2026 |
Est. primary completion date | April 10, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed advanced malignancies as follows: 1. Part 1 only: Participants with the select advanced malignancies as specified in the protocol. 2. Part 2 only: - Cohort 1 only: Participants with Stage III (unresectable) or Stage IV (metastatic) melanoma that is considered nonamenable to curative treatments or procedures. - Cohort 2 only: Participants with histologically or cytologically confirmed recurrent/metastatic SCCHN that is PD-L1 positive (CPS = 1) which is not amenable to local therapy with curative intent. - Participants must have experienced disease progression after treatment with standard therapies, or are intolerant to or ineligible for standard treatment: 1. Part 1: All available standard therapies, including anti-PD-(L)1 and platinum-based therapy, if applicable, that are known to confer clinical benefit. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance. 2. Part 2: Available standard therapies, including anti-PD-(L)1 and platinum-based therapy, if applicable, that are known to confer clinical benefit. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance. Part 2 participants may have received up to 2 prior systemic therapies in the a advanced/metastatic setting. - ECOG performance status of 0 or 1 - Part 2 only: Measurable disease according to RECIST v1.1. - Part 2 only: Willingness to undergo a fresh tumor biopsy at screening (core or excisional). - Part 2 only: Willingness to undergo a fresh tumor biopsy at screening and on-treatment in selected participant. - Willingness to avoid pregnancy or fathering children Exclusion Criteria: - Prior treatment with any LAG-3- or MHC Class II-directed therapy for current malignancy, or any prior malignancy. - Treatment with anticancer therapies or participation in another interventional clinical study within 28 days before the first administration of study treatment (this includes curative radiation to the thorax or systemic anticancer therapies). - Not recovered to = Grade 1 or baseline from residual toxicities of prior therapy (with exceptions specified in the protocol). - Not recovered adequately from toxicities and/or complications from surgical intervention before starting study treatment. - Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment. - Any known additional malignancy that is progressing or requires active treatment; history of other malignancy within 3 years of the first dose of study treatment (with exceptions specified in the protocol). - Evidence of interstitial lung disease or history of interstitial lung disease, or active, noninfectious pneumonitis. - Active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 2 years before the first dose of study treatment. - Untreated brain or CNS metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases). - Chronic treatment with systemic steroids (> 10 mg/day of prednisone or equivalent). |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques Universitaires Ucl Saint-Luc | Bruxelles | |
Belgium | Universitair Ziekenhuis Antwerpen (Uza) | Edegem | |
Belgium | Universitair Ziekenhuis Gent | Gent | |
Belgium | Universitair Ziekenhuis Brussel | Jette | |
Belgium | Chu Ucl Namur University Hospital Mont-Godinne | Yvoir | |
Italy | Centro Ricerche Cliniche Di Verona (Crc) | Verona | |
Spain | Hospital Quironsalud Barcelona | Barcelona | |
Spain | Ico Institut Catala D Oncologia | L'hospitalet de Llobregat | |
Spain | Centro Integral Oncologico Clara Campal | Madrid | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario Quironsalud Madrid | Pozuelo de Alarcón | |
United States | University of Texas Md Anderson Cancer Center | Houston | Texas |
United States | The Angeles Clinic and Research Institute | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Incyte Corporation |
United States, Belgium, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Occurrence of Dose Limiting Toxicities (DLTs) | Toxicities occurring during Part 1 will define tolerability. DLTs will be assessed for severity by the investigator using CTCAE v5.0 criteria. | Up to approximately 12 months | |
Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE is any Adverse Event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug. | Up to approximately 12 months | |
Primary | Number of Participants with Dose Interruptions due to TEAE | Dose interruptions will occur according to protocol guidelines. | Up to approximately 12 months | |
Primary | Number of Participants discontinue study due to TEAE | TEAE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. | Up to approximately 12 months | |
Secondary | Objective Response Rate (ORR) | Defined as having Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or Lugano criteria (B-cell lymphomas only). | Up to 12 months | |
Secondary | Disease Control Response (DCR) | Defined as having CR, PR, or Stable Disease (SD) as determined by the investigator by radiographic disease assessment according to RECIST v1.1. or Lugano criteria (B-cell lymphomas only). | Up to 12 months | |
Secondary | Duration of Response (DOR) | Defined as the time from earliest date of disease response (Completed Response or Partial Response) until earliest date of disease progression as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or Lugano criteria (B-cell lymphomas only) or death due to any cause if occurring sooner than progression. | Up to 12 months | |
Secondary | PK parameters: Cmax | Defined as the maximum (peak) plasma drug concentration | Up to 24 months | |
Secondary | PK parameters: tmax | Defined as the time to reach maximum (peak) plasma concentration following drug administration | Up to 24 months | |
Secondary | PK parameters: Cmin | Defined as concentration at the end of the dosing interval | Up to 24 months | |
Secondary | PK Parameters: AUC | Defined as the area under the plasma concentration-time curve | Up to 24 months | |
Secondary | PK Parameters: CL | Defined as the apparent total body clearance of the drug from plasma | Up to 24 months | |
Secondary | PK Parameters: Vz | Defined as apparent volume of distribution during terminal phase | Up to 24 months | |
Secondary | PK Parameters: t1/2 | Defined as Elimination half-life (to be used in one-or noncompartmental model) | Up to 24 months | |
Secondary | Receptor Occupancy | Defined as PD-1 receptor occupancy in peripheral blood samples. | Up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Completed |
NCT00948961 -
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
|
Phase 1/Phase 2 | |
Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
Terminated |
NCT02265510 -
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03907969 -
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
|
Phase 1/Phase 2 | |
Completed |
NCT03241173 -
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT02923349 -
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04025957 -
A Study of SHR-1501 in Patients With Advanced Tumors
|
Phase 1 | |
Recruiting |
NCT05048134 -
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00651664 -
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
|
Phase 1 | |
Not yet recruiting |
NCT06038058 -
A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00611793 -
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
Not yet recruiting |
NCT05987605 -
Clinical Study of 1A46 Drug Substance
|
Phase 1 | |
Terminated |
NCT02608268 -
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT03277352 -
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT04831996 -
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
|
Phase 1 | |
Recruiting |
NCT06468098 -
A Study of IBI363 in Subjects With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT02737501 -
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
|
Phase 3 | |
Completed |
NCT03158272 -
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
|
Phase 1 |